Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
ACER similar filings
- 22 May 19 Submission of Matters to a Vote of Security Holders
- 14 May 19 Acer Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
- 5 Apr 19 Regulation FD Disclosure
- 7 Mar 19 Acer Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
- 7 Jan 19 Regulation FD Disclosure
- 2 Jan 19 Acer Therapeutics Announces In-license of Osanetant from Sanofi
- 26 Dec 18 Acer Therapeutics Announces FDA Acceptance of NDA and Priority Review for EDSIVO™ for the Treatment of vEDS
Filing view
External links
Exhibit 16.1
March 7, 2019
Securities and Exchange Commission
Washington, D.C. 20549
Commissioners:
We have read Acer Therapeutics Inc.’s statements included under Item 4.01(a) of its Form 8-K filed on March 7, 2019 and we agree with such statements concerning our firm.
/s/ Wolf & Company, P.C.
Wolf & Company, P.C.
99 High Street
Boston, MA 02110